With special focus on T cell–redirection strategies for cancer treatment, the anti-TfR mAb has been developed to generate TfR-targeted bispecific T-cell engager antibodies (27) and the TfR-BiTE was proven to have the ability to induce the selective lysis of various TfR+ cancer cells through the activation of T cells (28), assuring the application of TfR as target for this type of immunotherapies. Here, TFRC is linked to cancer.